Doxorubicin liposomal - GP Pharm

Drug Profile

Doxorubicin liposomal - GP Pharm

Alternative Names: DX-GP; Sarcodoxome

Latest Information Update: 14 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GP Pharm
  • Class Anthracyclines; Cytostatic antibiotics; Doxorubicins; Small molecules
  • Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Soft tissue sarcoma

Most Recent Events

  • 14 Dec 2015 Phase II development is ongoing Spain
  • 21 Dec 2006 GP Pharm's liposomal doxorubicin has received Orphan Drug Status for Soft Tissue Sarcoma in the European Union
  • 21 Dec 2006 Phase-I clinical trials in Soft tissue sarcoma in Spain (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top